Ultragenyx Angelman Drug Fails Late-Stage Trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Ultragenyx announced earlier this week that its late-stage experimental drug for Angelman syndrome failed in its pivotal trial, a major blow to patients and the drug's maker.
- Angelman syndrome is a rare genetic disease that causes severe developmental delays, the condition the failed therapy was designed to treat.
- Mark Zylka, an Angelman researcher at the University of North Carolina, cautioned that the trial failure says nothing about other ongoing trials and shouldn't be interpreted as evidence the underlying mechanism is flawed.
- Experts said similar experimental medicines might still succeed, and success in Angelman could potentially extend genetic-medicine approaches to other neurological conditions to restore cognition, communication, and other skills in patients with intellectual disabilities.
Why it matters: For patients with Angelman syndrome and their families, the failure narrows the near-term treatment pipeline, though researchers explicitly argue the broader gene-therapy approach remains viable. Ultragenyx absorbs a high-profile rare-disease setback, while competing programs in Angelman continue and the wider thesis of genetic medicines for neurological and intellectual disabilities remains, as one expert put it, untested by this single outcome.
Ask SkimNews
